Review



pyroptosis inducer lps s7850 nigericin  (Selleck Chemicals)


Bioz Verified Symbol Selleck Chemicals is a verified supplier
Bioz Manufacturer Symbol Selleck Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Selleck Chemicals pyroptosis inducer lps s7850 nigericin
    GPR34 deletion promotes ferroptosis of ATC cells. (A, B) The CCK8 assay was used to determine the viability of BHT101 (A) and 8305C (B) cells with GPR34 knockdown after addition of the apoptosis inducer VCR, ferroptosis inducer RSL-3, autophagy inducer rapamycin, or <t>pyroptosis</t> inducer LPS + nigericin. (C, D) Representative images were presented of BHT101 (C) and 8305C cells (D) with GPR34 deletion treated with RSL-3. (E, F) The CCK8 assay was used to assess the responses of BHT101 (E) and 8305C cells (F) with GPR34 silencing to RSL-3 ± Fer-1. (G) IHC test on xenograft tumors was performed to identify the correlation between GPR34 and 4-HNE expression. (H, I) Lipid ROS (H) and GSH (I) levels in GPR34 deletion ATC cells. Ns, nonsignificant. p > 0.05, ⁣ ∗ p < 0.05, ⁣ ∗∗ p < 0.01, ⁣ ∗∗∗ p < 0.001.
    Pyroptosis Inducer Lps S7850 Nigericin, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 44 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin+sodium+salt/pmc12377955-32-9-19
    Average 95 stars, based on 44 article reviews
    pyroptosis inducer lps s7850 nigericin - by Bioz Stars, 2026-11
    95/100 stars

    Images

    1) Product Images from "GPR34 Stabilized by Deubiquitinase USP8 Suppresses Ferroptosis of ATC"

    Article Title: GPR34 Stabilized by Deubiquitinase USP8 Suppresses Ferroptosis of ATC

    Journal: Mediators of Inflammation

    doi: 10.1155/mi/5576056

    GPR34 deletion promotes ferroptosis of ATC cells. (A, B) The CCK8 assay was used to determine the viability of BHT101 (A) and 8305C (B) cells with GPR34 knockdown after addition of the apoptosis inducer VCR, ferroptosis inducer RSL-3, autophagy inducer rapamycin, or pyroptosis inducer LPS + nigericin. (C, D) Representative images were presented of BHT101 (C) and 8305C cells (D) with GPR34 deletion treated with RSL-3. (E, F) The CCK8 assay was used to assess the responses of BHT101 (E) and 8305C cells (F) with GPR34 silencing to RSL-3 ± Fer-1. (G) IHC test on xenograft tumors was performed to identify the correlation between GPR34 and 4-HNE expression. (H, I) Lipid ROS (H) and GSH (I) levels in GPR34 deletion ATC cells. Ns, nonsignificant. p > 0.05, ⁣ ∗ p < 0.05, ⁣ ∗∗ p < 0.01, ⁣ ∗∗∗ p < 0.001.
    Figure Legend Snippet: GPR34 deletion promotes ferroptosis of ATC cells. (A, B) The CCK8 assay was used to determine the viability of BHT101 (A) and 8305C (B) cells with GPR34 knockdown after addition of the apoptosis inducer VCR, ferroptosis inducer RSL-3, autophagy inducer rapamycin, or pyroptosis inducer LPS + nigericin. (C, D) Representative images were presented of BHT101 (C) and 8305C cells (D) with GPR34 deletion treated with RSL-3. (E, F) The CCK8 assay was used to assess the responses of BHT101 (E) and 8305C cells (F) with GPR34 silencing to RSL-3 ± Fer-1. (G) IHC test on xenograft tumors was performed to identify the correlation between GPR34 and 4-HNE expression. (H, I) Lipid ROS (H) and GSH (I) levels in GPR34 deletion ATC cells. Ns, nonsignificant. p > 0.05, ⁣ ∗ p < 0.05, ⁣ ∗∗ p < 0.01, ⁣ ∗∗∗ p < 0.001.

    Techniques Used: CCK-8 Assay, Knockdown, Expressing

    Related Articles

    other:

    Article Title: Phase separation drives NLRP3 inflammasome activation independently of Golgi localization
    Article Snippet: Nigericin, CL097, MCC950, and CY-09 were obtained from Selleck.

    In Vitro:

    Article Title: NRG1 Suppresses NLRP3 Inflammasome Activation and Endothelial-Mesenchymal Transition in Cerebral Ischemia-Reperfusion Injury: Association with the AKT/NF-κB Pathway
    Article Snippet: .. In vitro, ischemia was simulated using the OGD/R model. MCC950 (S7809; Selleck, USA), a selective NLRP3 inflammasome inhibitor, and Nigericin sodium salt (Nigericin) (S6653; Selleck), an NLRP3 inflammasome activator, were employed. ..

    Recombinant:

    Article Title: Cerebral organoid exosomes reversed behavioral deficits by repressing NLRP3 mediated neuroinflammation in stress models
    Article Snippet: .. 441 442 STAR★Methods 443 Key resources table 444 REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Jo urn al Pr e-p roo f 22 CD9 CST Cat# D8O1A CD63 Abcam Cat# ab134045 TSG101 Santa Cruz Cat# sc-7964 Arg-1 Boster Cat# BM4000 CD206 Abcam Cat# ab64693 iNOS Boster Cat# BA0362 GFAP Abcam Cat# ab7260 C3 Thermo Cat# PA5-21349 IBA-1 Protein tech; Wako Cat# 10904-1-AP; Cat# 019-19741 NLPR3 Protein tech Cat# 30109-1-AP Casp-1 Sigma Cat# AB1871 IL-1β ABclonal Cat# A16288 BDNF Abcam Cat# ab108319 TrkB R&D Cat# AF1494 SYN1 SYSY Cat# 106011 PSD95 SYSY Cat# 124003 SOX2 R&D Cat# AF2018-SP TBR2 Abcam Cat# ab216870 CTIP2 Abcam Cat# ab18465 PAX6 Abcam Cat# ab195045 MAP2 Sigma Cat# M4403 TUJ1 Abcam Cat# ab78078 FZD9 SAB Cat# 31503 GAPDH Protein tech Cat# 60004-1-Ig β-actin Santa Cruz Cat# sc-8432 DAPI Beyotime Cat# C1002 Chemicals, peptides, and recombinant proteins Nigericin Selleck Cat# S6653 Experimental models: Organisms/strains Male C57BL/6 mice SPF Biotechnology N/A Oligonucleotides Primers see Table S1 This paper N/A Deposited data Mass spectrometry data Mendeley Data DOI:10.17632/hn8gj5h5wr.1 Software and algorithms ImageJ NIH https://imagej.net/software/imagej/ GraphPad Prism (version 9.0) GraphPad Software https://www.graphpad.com/ ANY-Maze ANY-Maze Software https://www.any-maze.com/ R software R Software https://www.r-project.org/ 445 Resource availability 446 Jo urn al Pr e-p roo f 23 Lead Contact 447 Further information and requests for resources and reagents should be directed to and 448 will be fulfilled by the lead contact, Shuang Yu (yush@sibet.ac.cn). ..

    Mass Spectrometry:

    Article Title: Cerebral organoid exosomes reversed behavioral deficits by repressing NLRP3 mediated neuroinflammation in stress models
    Article Snippet: .. 441 442 STAR★Methods 443 Key resources table 444 REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Jo urn al Pr e-p roo f 22 CD9 CST Cat# D8O1A CD63 Abcam Cat# ab134045 TSG101 Santa Cruz Cat# sc-7964 Arg-1 Boster Cat# BM4000 CD206 Abcam Cat# ab64693 iNOS Boster Cat# BA0362 GFAP Abcam Cat# ab7260 C3 Thermo Cat# PA5-21349 IBA-1 Protein tech; Wako Cat# 10904-1-AP; Cat# 019-19741 NLPR3 Protein tech Cat# 30109-1-AP Casp-1 Sigma Cat# AB1871 IL-1β ABclonal Cat# A16288 BDNF Abcam Cat# ab108319 TrkB R&D Cat# AF1494 SYN1 SYSY Cat# 106011 PSD95 SYSY Cat# 124003 SOX2 R&D Cat# AF2018-SP TBR2 Abcam Cat# ab216870 CTIP2 Abcam Cat# ab18465 PAX6 Abcam Cat# ab195045 MAP2 Sigma Cat# M4403 TUJ1 Abcam Cat# ab78078 FZD9 SAB Cat# 31503 GAPDH Protein tech Cat# 60004-1-Ig β-actin Santa Cruz Cat# sc-8432 DAPI Beyotime Cat# C1002 Chemicals, peptides, and recombinant proteins Nigericin Selleck Cat# S6653 Experimental models: Organisms/strains Male C57BL/6 mice SPF Biotechnology N/A Oligonucleotides Primers see Table S1 This paper N/A Deposited data Mass spectrometry data Mendeley Data DOI:10.17632/hn8gj5h5wr.1 Software and algorithms ImageJ NIH https://imagej.net/software/imagej/ GraphPad Prism (version 9.0) GraphPad Software https://www.graphpad.com/ ANY-Maze ANY-Maze Software https://www.any-maze.com/ R software R Software https://www.r-project.org/ 445 Resource availability 446 Jo urn al Pr e-p roo f 23 Lead Contact 447 Further information and requests for resources and reagents should be directed to and 448 will be fulfilled by the lead contact, Shuang Yu (yush@sibet.ac.cn). ..

    Software:

    Article Title: Cerebral organoid exosomes reversed behavioral deficits by repressing NLRP3 mediated neuroinflammation in stress models
    Article Snippet: .. 441 442 STAR★Methods 443 Key resources table 444 REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Jo urn al Pr e-p roo f 22 CD9 CST Cat# D8O1A CD63 Abcam Cat# ab134045 TSG101 Santa Cruz Cat# sc-7964 Arg-1 Boster Cat# BM4000 CD206 Abcam Cat# ab64693 iNOS Boster Cat# BA0362 GFAP Abcam Cat# ab7260 C3 Thermo Cat# PA5-21349 IBA-1 Protein tech; Wako Cat# 10904-1-AP; Cat# 019-19741 NLPR3 Protein tech Cat# 30109-1-AP Casp-1 Sigma Cat# AB1871 IL-1β ABclonal Cat# A16288 BDNF Abcam Cat# ab108319 TrkB R&D Cat# AF1494 SYN1 SYSY Cat# 106011 PSD95 SYSY Cat# 124003 SOX2 R&D Cat# AF2018-SP TBR2 Abcam Cat# ab216870 CTIP2 Abcam Cat# ab18465 PAX6 Abcam Cat# ab195045 MAP2 Sigma Cat# M4403 TUJ1 Abcam Cat# ab78078 FZD9 SAB Cat# 31503 GAPDH Protein tech Cat# 60004-1-Ig β-actin Santa Cruz Cat# sc-8432 DAPI Beyotime Cat# C1002 Chemicals, peptides, and recombinant proteins Nigericin Selleck Cat# S6653 Experimental models: Organisms/strains Male C57BL/6 mice SPF Biotechnology N/A Oligonucleotides Primers see Table S1 This paper N/A Deposited data Mass spectrometry data Mendeley Data DOI:10.17632/hn8gj5h5wr.1 Software and algorithms ImageJ NIH https://imagej.net/software/imagej/ GraphPad Prism (version 9.0) GraphPad Software https://www.graphpad.com/ ANY-Maze ANY-Maze Software https://www.any-maze.com/ R software R Software https://www.r-project.org/ 445 Resource availability 446 Jo urn al Pr e-p roo f 23 Lead Contact 447 Further information and requests for resources and reagents should be directed to and 448 will be fulfilled by the lead contact, Shuang Yu (yush@sibet.ac.cn). ..



    Similar Products

    94
    TargetMol nigericin
    Identification of a benzo[ d ]imidazo[1,2‐ a ]imidazole scaffold with selective anti‐ferroptotic activity. (a) Protective effects of a focused nitrogen‐containing heterocyclic compound library (10 µ m , 24 h) against RSL3‐induced ferroptosis (0.2 µ m , 24 h) in HT‐1080 cells, as determined by the CCK‐8 assay. The cell viability of the RSL3‐treated group is indicated by the red dashed line. (b) Chemical structures of representative active and inactive compounds sharing the benzo[ d ]imidazo[1,2‐ a ]imidazole core scaffold. (c) Chemical structures and effects against RSL3‐induced ferroptosis of scaffold‐modified derivatives. Inhibitory activity of selected compounds against ferroptosis induced by 10 µ m Erastin (d) and 1 µ m FIN56 (e) in HT‐1080 cells. 1 µ m Fer‐1 was used as a positive control. (f) Inhibitory activity of selected compounds against apoptosis induced by 1 µM Staurosporine (STS) in HT‐1080 cells. 100 µ m Z‐VAD‐FMK was used as a positive control. (g) Inhibitory activity of selected compounds against necrosis induced by 3 mM H 2 O 2 in HT‐1080 cells. (h) Inhibitory activity of selected compounds against cuproptosis induced by Elesclomol‐Cu 2+ (1 µ m , 1:1) in HT‐1080 cells. 10 µ m Ammonium tetrathiomolybdate (TTM) was used as a positive control. (i) Inhibitory activity of selected compounds against parthanatos induced by 300 µ m methyl methanesulfonate (MMS) in HT‐1080 cells. (j) Inhibitory activity of selected compounds against necroptosis induced by TNF‐α/SM‐164/Z‐VAD‐FMK in L‐929 cells. 30 µ m Necrostatin‐1 (Nec‐1) was used as a positive control. (k) Inhibitory activity of selected compounds against pyroptosis induced by LPS (500 ng/mL, 4 <t>h)/Nigericin</t> (10 µ m , 2 h) in BMDM cells. 30 µ m Necrosulfonamide (NSA) was used as a positive control. Data in panels (d–k) are presented as mean ± SD ( n = 3). ### p < 0.001 vs. the Control group; *** p < 0.001 vs. the Model group.
    Nigericin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin/pmc13771665-192-6-17
    Average 94 stars, based on 1 article reviews
    nigericin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    99
    InvivoGen nigericin
    Preparation and mechanism of HM‐LCPs platform. First, LCPs are formulated using an oxygen‐carrying perfluorohexane (PFH) nanoemulsion stabilized by a phosphatidylcholine liposome loaded with sonosensitizer chlorin e6 (Ce6) (LC). Meanwhile, murine peritoneal macrophages (PMs) are stimulated with lipopolysaccharide (LPS) and subsequently treated with <t>nigericin</t> in the presence of glycine to generate hyperactivated macrophages (HMs). Unlike standard LPS‐stimulated PMs (L‐PMs), HMs exhibit reversible pore dynamics accompanied by IL‐1β secretion and are not subject to IL‐4 suppression. Finally, the LCPs are conjugated onto the HM surface via a metal‐phenolic network reaction to fabricate HM‐LCP platforms. Following intratumoral (i.t.) administration, HM‐LCPs exert therapeutic effects in two sequential phases: (І) Phase I (HM‐mediated immunoregulation) : HM‐LCPs sustainably release IL‐1β despite the immunosuppressive tumor microenvironment (TME). This directly kills 4T1 cells and induces immunogenic cell death (ICD), thereby activating antitumor immunity. (ІІ) Phase II (SDT‐induced tumor cell lysis and ECM degradation) : Upon ultrasound (US) irradiation, HM‐LCPs generate reactive oxygen species (ROS) via sonodynamic therapy (SDT). This not only kills both HMs and tumor cells, augmenting the ICD effect, but also degrades the extracellular matrix (ECM). Ultimately, this dual‐phase action synergistically combines the intrinsic immunoregulatory activity of HMs with the SDT‐induced oxidative stress from LCPs, significantly inhibiting primary tumor growth, reversing tumor immunosuppression, enhancing CD8 + T cell infiltration, and inducing potent abscopal effects against distant tumors. Created with BioRender.com under an Agreement License (No. IO2AAQFDH6).
    Nigericin, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin/pmc13771408-191-0-6
    Average 99 stars, based on 1 article reviews
    nigericin - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    MedChemExpress nigericin sodium salt
    Siglec-E deficiency in neutrophils exacerbates <t>nigericin-induced</t> NET overactivation. ( A , B ) BP-1 regulates MPO expression in wild-type neutrophils and associates with SHP-1 (IF + Quantification); ( C ) Siglec-E PKO Mouse Generation Protocol; ( D ) Target Gene Identification in Siglec-E PKO Mice; ( E) Purity Assessment of Bone Marrow-Derived Neutrophils; ( F , H ) BP-1 reduces MPO-associated mean fluorescence intensity in wild-type neutrophils stimulated with nigericin (IF + Quantification); ( G , I ) BP-1 did not reduce MPO-associated mean fluorescence intensity in Siglec-E PKO Mice neutrophils stimulated with nigericin (IF + Quantification); ( J ) SHP-1–Siglec-E Interaction: Co-IP from Nigericin-stimulated neutrophils using Anti-SHP-1 beads; ( K ) Western blot Analysis of Co-Immunoprecipitated Complexes, each lane represents an individual biological sample. Data were presented as the mean ± SD (n = 3). Statistics were determined by one-way ANOVA. * p < 0.05, ** p < 0.01, and *** p < 0.001.
    Nigericin Sodium Salt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin+sodium+salt/pmc13765300-103-44-48
    Average 96 stars, based on 1 article reviews
    nigericin sodium salt - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    98
    MedChemExpress nigericin
    Siglec-E deficiency in neutrophils exacerbates <t>nigericin-induced</t> NET overactivation. ( A , B ) BP-1 regulates MPO expression in wild-type neutrophils and associates with SHP-1 (IF + Quantification); ( C ) Siglec-E PKO Mouse Generation Protocol; ( D ) Target Gene Identification in Siglec-E PKO Mice; ( E) Purity Assessment of Bone Marrow-Derived Neutrophils; ( F , H ) BP-1 reduces MPO-associated mean fluorescence intensity in wild-type neutrophils stimulated with nigericin (IF + Quantification); ( G , I ) BP-1 did not reduce MPO-associated mean fluorescence intensity in Siglec-E PKO Mice neutrophils stimulated with nigericin (IF + Quantification); ( J ) SHP-1–Siglec-E Interaction: Co-IP from Nigericin-stimulated neutrophils using Anti-SHP-1 beads; ( K ) Western blot Analysis of Co-Immunoprecipitated Complexes, each lane represents an individual biological sample. Data were presented as the mean ± SD (n = 3). Statistics were determined by one-way ANOVA. * p < 0.05, ** p < 0.01, and *** p < 0.001.
    Nigericin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin/pm42957055-95-14-15
    Average 98 stars, based on 1 article reviews
    nigericin - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    98
    MedChemExpress cycloheximide
    Siglec-E deficiency in neutrophils exacerbates <t>nigericin-induced</t> NET overactivation. ( A , B ) BP-1 regulates MPO expression in wild-type neutrophils and associates with SHP-1 (IF + Quantification); ( C ) Siglec-E PKO Mouse Generation Protocol; ( D ) Target Gene Identification in Siglec-E PKO Mice; ( E) Purity Assessment of Bone Marrow-Derived Neutrophils; ( F , H ) BP-1 reduces MPO-associated mean fluorescence intensity in wild-type neutrophils stimulated with nigericin (IF + Quantification); ( G , I ) BP-1 did not reduce MPO-associated mean fluorescence intensity in Siglec-E PKO Mice neutrophils stimulated with nigericin (IF + Quantification); ( J ) SHP-1–Siglec-E Interaction: Co-IP from Nigericin-stimulated neutrophils using Anti-SHP-1 beads; ( K ) Western blot Analysis of Co-Immunoprecipitated Complexes, each lane represents an individual biological sample. Data were presented as the mean ± SD (n = 3). Statistics were determined by one-way ANOVA. * p < 0.05, ** p < 0.01, and *** p < 0.001.
    Cycloheximide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin/pm42869164-47-9-15
    Average 98 stars, based on 1 article reviews
    cycloheximide - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    98
    MedChemExpress pyroptosis inducer nigericin
    Microglia‐derived migrasomal C1qc induces endothelial injury following intracerebral haemorrhage. After the occurrence of ICH, microglia secrete migrasomes enriched with C1qc. These migrasomes adhere to brain microvascular endothelial cells. Intracellularly, the delivered C1qc triggers the <t>Nlrp3/Caspase‐1/GSDMD</t> pyroptotic cascade. This signalling leads to GSDMD‐N‐mediated pore formation and endothelial <t>pyroptosis,</t> ultimately causing the disruption of tight junctions and blood–brain barrier breakdown.
    Pyroptosis Inducer Nigericin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nigericin/Nigericin/pmc13645951-115-0-5
    Average 98 stars, based on 1 article reviews
    pyroptosis inducer nigericin - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    Image Search Results


    Identification of a benzo[ d ]imidazo[1,2‐ a ]imidazole scaffold with selective anti‐ferroptotic activity. (a) Protective effects of a focused nitrogen‐containing heterocyclic compound library (10 µ m , 24 h) against RSL3‐induced ferroptosis (0.2 µ m , 24 h) in HT‐1080 cells, as determined by the CCK‐8 assay. The cell viability of the RSL3‐treated group is indicated by the red dashed line. (b) Chemical structures of representative active and inactive compounds sharing the benzo[ d ]imidazo[1,2‐ a ]imidazole core scaffold. (c) Chemical structures and effects against RSL3‐induced ferroptosis of scaffold‐modified derivatives. Inhibitory activity of selected compounds against ferroptosis induced by 10 µ m Erastin (d) and 1 µ m FIN56 (e) in HT‐1080 cells. 1 µ m Fer‐1 was used as a positive control. (f) Inhibitory activity of selected compounds against apoptosis induced by 1 µM Staurosporine (STS) in HT‐1080 cells. 100 µ m Z‐VAD‐FMK was used as a positive control. (g) Inhibitory activity of selected compounds against necrosis induced by 3 mM H 2 O 2 in HT‐1080 cells. (h) Inhibitory activity of selected compounds against cuproptosis induced by Elesclomol‐Cu 2+ (1 µ m , 1:1) in HT‐1080 cells. 10 µ m Ammonium tetrathiomolybdate (TTM) was used as a positive control. (i) Inhibitory activity of selected compounds against parthanatos induced by 300 µ m methyl methanesulfonate (MMS) in HT‐1080 cells. (j) Inhibitory activity of selected compounds against necroptosis induced by TNF‐α/SM‐164/Z‐VAD‐FMK in L‐929 cells. 30 µ m Necrostatin‐1 (Nec‐1) was used as a positive control. (k) Inhibitory activity of selected compounds against pyroptosis induced by LPS (500 ng/mL, 4 h)/Nigericin (10 µ m , 2 h) in BMDM cells. 30 µ m Necrosulfonamide (NSA) was used as a positive control. Data in panels (d–k) are presented as mean ± SD ( n = 3). ### p < 0.001 vs. the Control group; *** p < 0.001 vs. the Model group.

    Journal: Advanced Science

    Article Title: Discovery of an NCoA4 Ligand That Suppresses Ferroptosis and Attenuates Kidney Injury by Limiting Ferritinophagy‐Mediated Iron Release

    doi: 10.1002/advs.78710

    Figure Lengend Snippet: Identification of a benzo[ d ]imidazo[1,2‐ a ]imidazole scaffold with selective anti‐ferroptotic activity. (a) Protective effects of a focused nitrogen‐containing heterocyclic compound library (10 µ m , 24 h) against RSL3‐induced ferroptosis (0.2 µ m , 24 h) in HT‐1080 cells, as determined by the CCK‐8 assay. The cell viability of the RSL3‐treated group is indicated by the red dashed line. (b) Chemical structures of representative active and inactive compounds sharing the benzo[ d ]imidazo[1,2‐ a ]imidazole core scaffold. (c) Chemical structures and effects against RSL3‐induced ferroptosis of scaffold‐modified derivatives. Inhibitory activity of selected compounds against ferroptosis induced by 10 µ m Erastin (d) and 1 µ m FIN56 (e) in HT‐1080 cells. 1 µ m Fer‐1 was used as a positive control. (f) Inhibitory activity of selected compounds against apoptosis induced by 1 µM Staurosporine (STS) in HT‐1080 cells. 100 µ m Z‐VAD‐FMK was used as a positive control. (g) Inhibitory activity of selected compounds against necrosis induced by 3 mM H 2 O 2 in HT‐1080 cells. (h) Inhibitory activity of selected compounds against cuproptosis induced by Elesclomol‐Cu 2+ (1 µ m , 1:1) in HT‐1080 cells. 10 µ m Ammonium tetrathiomolybdate (TTM) was used as a positive control. (i) Inhibitory activity of selected compounds against parthanatos induced by 300 µ m methyl methanesulfonate (MMS) in HT‐1080 cells. (j) Inhibitory activity of selected compounds against necroptosis induced by TNF‐α/SM‐164/Z‐VAD‐FMK in L‐929 cells. 30 µ m Necrostatin‐1 (Nec‐1) was used as a positive control. (k) Inhibitory activity of selected compounds against pyroptosis induced by LPS (500 ng/mL, 4 h)/Nigericin (10 µ m , 2 h) in BMDM cells. 30 µ m Necrosulfonamide (NSA) was used as a positive control. Data in panels (d–k) are presented as mean ± SD ( n = 3). ### p < 0.001 vs. the Control group; *** p < 0.001 vs. the Model group.

    Article Snippet: Staurosporine (T6680), Z‐VAD‐FMK (T7020), elesclomol (T6170), nigericin ( T16323 ), and DFO mesylate (T1637) were purchased from TargetMol.

    Techniques: Activity Assay, Drug discovery, CCK-8 Assay, Modification, Positive Control, Control

    Preparation and mechanism of HM‐LCPs platform. First, LCPs are formulated using an oxygen‐carrying perfluorohexane (PFH) nanoemulsion stabilized by a phosphatidylcholine liposome loaded with sonosensitizer chlorin e6 (Ce6) (LC). Meanwhile, murine peritoneal macrophages (PMs) are stimulated with lipopolysaccharide (LPS) and subsequently treated with nigericin in the presence of glycine to generate hyperactivated macrophages (HMs). Unlike standard LPS‐stimulated PMs (L‐PMs), HMs exhibit reversible pore dynamics accompanied by IL‐1β secretion and are not subject to IL‐4 suppression. Finally, the LCPs are conjugated onto the HM surface via a metal‐phenolic network reaction to fabricate HM‐LCP platforms. Following intratumoral (i.t.) administration, HM‐LCPs exert therapeutic effects in two sequential phases: (І) Phase I (HM‐mediated immunoregulation) : HM‐LCPs sustainably release IL‐1β despite the immunosuppressive tumor microenvironment (TME). This directly kills 4T1 cells and induces immunogenic cell death (ICD), thereby activating antitumor immunity. (ІІ) Phase II (SDT‐induced tumor cell lysis and ECM degradation) : Upon ultrasound (US) irradiation, HM‐LCPs generate reactive oxygen species (ROS) via sonodynamic therapy (SDT). This not only kills both HMs and tumor cells, augmenting the ICD effect, but also degrades the extracellular matrix (ECM). Ultimately, this dual‐phase action synergistically combines the intrinsic immunoregulatory activity of HMs with the SDT‐induced oxidative stress from LCPs, significantly inhibiting primary tumor growth, reversing tumor immunosuppression, enhancing CD8 + T cell infiltration, and inducing potent abscopal effects against distant tumors. Created with BioRender.com under an Agreement License (No. IO2AAQFDH6).

    Journal: Advanced Science

    Article Title: Hyperactivated Macrophage‐Based Biohybrid Platform for Spatiotemporally Controlled Immunoregulatory and Sonodynamic Therapy of Cancer

    doi: 10.1002/advs.78777

    Figure Lengend Snippet: Preparation and mechanism of HM‐LCPs platform. First, LCPs are formulated using an oxygen‐carrying perfluorohexane (PFH) nanoemulsion stabilized by a phosphatidylcholine liposome loaded with sonosensitizer chlorin e6 (Ce6) (LC). Meanwhile, murine peritoneal macrophages (PMs) are stimulated with lipopolysaccharide (LPS) and subsequently treated with nigericin in the presence of glycine to generate hyperactivated macrophages (HMs). Unlike standard LPS‐stimulated PMs (L‐PMs), HMs exhibit reversible pore dynamics accompanied by IL‐1β secretion and are not subject to IL‐4 suppression. Finally, the LCPs are conjugated onto the HM surface via a metal‐phenolic network reaction to fabricate HM‐LCP platforms. Following intratumoral (i.t.) administration, HM‐LCPs exert therapeutic effects in two sequential phases: (І) Phase I (HM‐mediated immunoregulation) : HM‐LCPs sustainably release IL‐1β despite the immunosuppressive tumor microenvironment (TME). This directly kills 4T1 cells and induces immunogenic cell death (ICD), thereby activating antitumor immunity. (ІІ) Phase II (SDT‐induced tumor cell lysis and ECM degradation) : Upon ultrasound (US) irradiation, HM‐LCPs generate reactive oxygen species (ROS) via sonodynamic therapy (SDT). This not only kills both HMs and tumor cells, augmenting the ICD effect, but also degrades the extracellular matrix (ECM). Ultimately, this dual‐phase action synergistically combines the intrinsic immunoregulatory activity of HMs with the SDT‐induced oxidative stress from LCPs, significantly inhibiting primary tumor growth, reversing tumor immunosuppression, enhancing CD8 + T cell infiltration, and inducing potent abscopal effects against distant tumors. Created with BioRender.com under an Agreement License (No. IO2AAQFDH6).

    Article Snippet: Nigericin (Nig, tlrl‐nig) was purchased from InvivoGen (America).

    Techniques: Lysis, Irradiation, Activity Assay

    Siglec-E deficiency in neutrophils exacerbates nigericin-induced NET overactivation. ( A , B ) BP-1 regulates MPO expression in wild-type neutrophils and associates with SHP-1 (IF + Quantification); ( C ) Siglec-E PKO Mouse Generation Protocol; ( D ) Target Gene Identification in Siglec-E PKO Mice; ( E) Purity Assessment of Bone Marrow-Derived Neutrophils; ( F , H ) BP-1 reduces MPO-associated mean fluorescence intensity in wild-type neutrophils stimulated with nigericin (IF + Quantification); ( G , I ) BP-1 did not reduce MPO-associated mean fluorescence intensity in Siglec-E PKO Mice neutrophils stimulated with nigericin (IF + Quantification); ( J ) SHP-1–Siglec-E Interaction: Co-IP from Nigericin-stimulated neutrophils using Anti-SHP-1 beads; ( K ) Western blot Analysis of Co-Immunoprecipitated Complexes, each lane represents an individual biological sample. Data were presented as the mean ± SD (n = 3). Statistics were determined by one-way ANOVA. * p < 0.05, ** p < 0.01, and *** p < 0.001.

    Journal: Molecules

    Article Title: Bupleurum chinense DC. –Derived Acidic Polysaccharide: Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Activation of Siglec-E

    doi: 10.3390/molecules31213989

    Figure Lengend Snippet: Siglec-E deficiency in neutrophils exacerbates nigericin-induced NET overactivation. ( A , B ) BP-1 regulates MPO expression in wild-type neutrophils and associates with SHP-1 (IF + Quantification); ( C ) Siglec-E PKO Mouse Generation Protocol; ( D ) Target Gene Identification in Siglec-E PKO Mice; ( E) Purity Assessment of Bone Marrow-Derived Neutrophils; ( F , H ) BP-1 reduces MPO-associated mean fluorescence intensity in wild-type neutrophils stimulated with nigericin (IF + Quantification); ( G , I ) BP-1 did not reduce MPO-associated mean fluorescence intensity in Siglec-E PKO Mice neutrophils stimulated with nigericin (IF + Quantification); ( J ) SHP-1–Siglec-E Interaction: Co-IP from Nigericin-stimulated neutrophils using Anti-SHP-1 beads; ( K ) Western blot Analysis of Co-Immunoprecipitated Complexes, each lane represents an individual biological sample. Data were presented as the mean ± SD (n = 3). Statistics were determined by one-way ANOVA. * p < 0.05, ** p < 0.01, and *** p < 0.001.

    Article Snippet: was purchased from Chongqing Tongjunge Pharmacy Chain Co., Ltd. (Chongqing, China) and authenticated using morphological and microscopic identification in accordance with the Chinese Pharmacopoeia by Prof. Peng Li from Army Medical University; LPS ( Escherichia coli O127:B8, L3129; Sigma-Aldrich, St. Louis, MO, United States), nigericin sodium salt (HY-100381; MCE, Monmouth Junction, NJ, United States), dexamethasone (IF1010; Solarbio, Beijing, China) and sytox green (AP6325; alphabio, Seattle, WA, United States) were used in cell and animal experiments; TNF-α (ML002095V; Novus Biologicals, Centennial, CO, United States) and IL-1β (ML301814V; Novus Biologicals, Centennial, CO, United States) were used for ELISA detection; The APC-conjugated Ly6G monoclonal antibody (AC0276; Abclonal Technology, Wuhan, China) was used for flow cytometry and immunofluorescence staining; anti-PAD4 antibody (A1906; abclonal, Wuhan, China), anti-MPO antibody (AF3667; R&D, Minneapolis, MN, United States), anti-Cit H3 antibody (ab281584; Abcam, Cambridge, United Kingdom), anti-β-actin antibody (AF0003; Beyotime Biotechnology, Shanghai, China), GAPDH antibody (AF0006; Beyotime Biotechnology, Shanghai, China), HRP-conjugated goat anti-mouse/rabbit IgG (H+L) (9116; Cell Signaling Technology, Danvers, MA, United States), and Alexa Fluor 647 Affinipure goat anti-rabbit IgG (H+L) (111-005-047; Jackson ImmunoResearch, West Grove, PA, United States), were used for Western blotting and immunofluorescence staining; Human Siglec-9 Fc (1139-SL-050; R&D Systems, Minneapolis, MN, United States), murine Siglec-E Fc (5806-SL-050; R&D Systems, Minneapolis, MN, United States), murine Siglec-E antibody (sc-377477; Santa Cruz Biotechnology, Dallas, TX, United States), and SHP-1 antibody (ab227503; Abcam, Cambridge, United Kingdom) were used for binding and immunoprecipitation (IP) experiments.

    Techniques: Expressing, Derivative Assay, Fluorescence, Co-Immunoprecipitation Assay, Western Blot, Analysis, Immunoprecipitation

    Microglia‐derived migrasomal C1qc induces endothelial injury following intracerebral haemorrhage. After the occurrence of ICH, microglia secrete migrasomes enriched with C1qc. These migrasomes adhere to brain microvascular endothelial cells. Intracellularly, the delivered C1qc triggers the Nlrp3/Caspase‐1/GSDMD pyroptotic cascade. This signalling leads to GSDMD‐N‐mediated pore formation and endothelial pyroptosis, ultimately causing the disruption of tight junctions and blood–brain barrier breakdown.

    Journal: Journal of Extracellular Vesicles

    Article Title: C1qc Mediates Blood–Brain Barrier Disruption in a Mouse Model of Intracerebral Haemorrhage Through Microglia‐Derived Migrasomes

    doi: 10.1002/jev2.70377

    Figure Lengend Snippet: Microglia‐derived migrasomal C1qc induces endothelial injury following intracerebral haemorrhage. After the occurrence of ICH, microglia secrete migrasomes enriched with C1qc. These migrasomes adhere to brain microvascular endothelial cells. Intracellularly, the delivered C1qc triggers the Nlrp3/Caspase‐1/GSDMD pyroptotic cascade. This signalling leads to GSDMD‐N‐mediated pore formation and endothelial pyroptosis, ultimately causing the disruption of tight junctions and blood–brain barrier breakdown.

    Article Snippet: Pyroptosis Inducer—Nigericin (Nlrp3 activator) (HY‐127019; MCE Med‐Chem Express, USA).

    Techniques: Derivative Assay, Disruption